LOS ANGELES, CA--(Marketwired - October 27, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Rik J. Deitsch, CEO of Nutra Pharma Corporation (NPHC), operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, (see here: www.NutraPharma.com). The video interview was recorded on Wednesday, October 14th, 2015 On-Location in Florida.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
Nutra Pharma Corp. -- Biotechnology Company Marketing Nyloxin® and Pet Pain-Away in Over-the-Counter and Pain Management Markets
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. Company description and for additional information about Nutra Pharma, visit:
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.
Embedded Video Available: https://www.youtube.com/watch?v=TM-3N-SPiUY
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Providing RPI-78M under compassionate release to patients enrolled in the Adrenomyeloneuropathy (AMN) clinical study should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.